The therapeutic management of rheumatoid arthritis has changed over the past 30 years, yet, comorbidities persist. In this quiz, we focus on findings from a new study that examines trends in clinical and patient-reported outcomes for early RA.
Long-term use of tumor necrosis factor inhibitors (TNFi) may show radiographic progression benefit in axial spondyloarthritis, say researchers recently writing in Arthritis & Rheumatology.
The practice of systematically tapering biological disease modifying antirheumatic drugs (bDMARDs) in all patients with inflammatory arthritis who have reached a certain disease activity target may not be supported by current evidence, according to a review published recently in Autoimmunity Reviews
The internationally recommended Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cutoff of four and above may not be applicable when initiating treatment with the tumor necrosis factor alpha inhibitor (TNFi) golimumab (Simponi, Janssen), say researchers recently writing in The Journal of Rheumatology.
Neither intermittent nor daily dosing of vitamin D alone was associated with reduced risk of fracture, but daily supplementation with both vitamin D and calcium showed promise in a study recently published in JAMA Network Open.
Disease activity measures still don’t appear to be entirely aligned with patient perceptions of pain and disease activity, shows a study featured in today’s news roundup. Researchers writing in Rheumatology say that condition improvements seen in objective measures of rheumatoid arthritis (RA) disease activity over the past three decades, do not match improvements in patient reported outcomes such as mental health, functional disability, overall disease activity, pain and vitality/fatigue. Learn more about this and other recently published studies on rheumatoid arthritis.
Women with rheumatoid arthritis who adhered to a defined program involving diagnostic, therapeutic, and prenatal care recommendations restored the risk of adverse pregnancy outcomes to that expected in the general population, say researchers recently writing in Arthritis Care & Research.
In patients with moderate to severe systemic lupus erythematosus (SLE), anifrolumab (AstraZeneca) was superior to placebo for improving overall disease activity, skin disease and oral corticosteroid tapering, say researchers writing in the New England Journal of Medicine.
There is insufficient evidence to support long-term effects on pain and functioning of low-dose radiation therapy for hand and knee osteoarthritis, say researchers writing in The Lancet Rheumatology.
Simple hip motion tests and observing for pain during that motion were helpful in identifying patients most likely to have hip osteoarthritis on plain radiography, say researchers recently writing in the Journal of the American Medical Association.